Company: QTIWW
Filing Date: 2025-01-31
Form Type: S-1/A
Source: 0001628280-25-003316
Chunk: 424

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-01-31
Form: S-1/A
Chunk 424
---
            36,198 |     | $    |  78,941 |
| Selling, general and administrative |     |      |            104,955 |     |      | 169,162 |     |      |           129,989 |     |      | 533,789 |
|                                     |     | $    |            127,203 |     | $    | 195,475 |     | $    |           166,187 |     | $    | 612,730 |

Nostock-based compensation expense was capitalized to inventory for three and nine months ended September 30, 2024 and 2023.

As of September 30, 2024, the total unrecognized compensation cost related to all nonvested stock options was $ 846,533and the weighted-average period over which it is expected to be recognized is 2.3years.

#### 13.

#### National Institutes of Health Subaward
On August 18, 2022, the Company was awarded a grant of up to $ 1,078,347as a subaward through the Board of Trustees of the University of Illinois for the purpose of developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy. The grant is a cost reimbursement subaward that is allocated annually over five years, subject to the availability of funds and satisfactory progress of the project. The award expires July 31, 2027 and may be terminated by either party with 30days written notice. Any grant proceeds received do not require repayment. As of September 30, 2024 , the Company incurred total costs of $ 385,280against the year one allocation of $ 351,994and against the year two allocation of $ 194,566. During the three months ended September 30, 2024 , the Company incurred costs of $ 3,359, of which $ 3,359of grant income was recognized as an offset to research and development expense and $ 0was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. During the three months ended September 30, 2023, the Company incurred costs of $ 151,996, of which $ 128,769of grant income was recognized as an offset to research and development expense and $ 23,227was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. During the nine months ended September